Compare LBRX & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRX | SSII |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | India |
| Employees | 27 | 483 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 774.5M |
| IPO Year | N/A | N/A |
| Metric | LBRX | SSII |
|---|---|---|
| Price | $27.89 | $4.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $46.60 | N/A |
| AVG Volume (30 Days) | ★ 140.2K | 37.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $3.02 |
| 52 Week High | $33.47 | $11.87 |
| Indicator | LBRX | SSII |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 41.73 |
| Support Level | $22.39 | $3.70 |
| Resistance Level | $33.47 | $5.14 |
| Average True Range (ATR) | 1.68 | 0.26 |
| MACD | -0.60 | 0.01 |
| Stochastic Oscillator | 11.96 | 43.58 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.